Model for neurodegenerative disorders
US7847146B2 · kind B2 · utility
0Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2004 |
| Grant date | Dec 7, 2010 |
| Priority date | — |
| Expiry date | May 25, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention discloses a double transgenic fly that expresses both Tau protein and the human Aβ42 peptide of human amyloid-β precursor protein (APP). The double transgenic flies of the present invention display a synergistic altered phenotype as compared to the altered phenotype displayed by transgenic flies expressing either Tau or human Aβ42 alone, and thus provide for an improved model for neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying for therapeutic compounds to treat neurodegenerative disorders using the double transgenic flies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.